Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Wealth accumulation is achievable even for low income earners. Discover practical tips designed to enhance your financial growth.
17,162 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
When insiders trade shares, investors often wonder what it means for the stock. This guide breaks down the latest LeM...
Piper Sandler trimmed its Upstart price target to $46 after a softer Q1 EBITDA print, but kept an Overweight rating a...
May 2026 brings a packed streaming slate as platforms roll out new originals and surprises, shaping market chatter ar...
H&R Block’s Q3 results set the tone for block (hrb) 2026 earnings. This guide breaks down the numbers, strategy, and ...
Qualcomm is trading at a discount to peers while building a strong AI silicon footprint. With a June Investor Day and...
Micron Technology has captured investor attention with a dramatic price rally. This guide breaks down what a stock sp...
If SpaceX goes public, many investors want a straightforward path to participate. This guide lays out practical, safe...
A sudden price glitch on a popular trading app sent bitcoin price crashes near zero for a moment, leaving traders puz...
Crypto traders are weighing ripple (xrp) solana (sol) as summer enters. The rivals push higher, but investors cite di...
AMD has surged dramatically, but the AI data-center boom could still offer upside. This guide explores whether late a...
This article breaks down United Parks PRKS 2026 Q1 earnings, highlighting revenue growth, margins, and the drivers sh...